Hongliang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongliang Chen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Mingdi Zhang
Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases
12 shared publicationsMaoli Wang
Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
10 shared publicationsKejin Wu
Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
7 shared publicationsPeng Zhang
Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, People’s Republic of China
6 shared publicationsFang Bai
Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
4 shared publicationsJingjing Yuan
Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases
4 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1742661
YKT6 promotes breast cancer progression and is associated with poor prognosis and immune infiltration
Background: YKT6 is markedly overexpressed across multiple tumor types and plays a role in driving their progression. However, the correlation between YKT6 and breast cancer remains poorly understood. Therefore, we aimed to investigate the potential prognostic value and biological function of YKT6 gene in breast cancer. Methods: Public datasets, clinic sample and tissue microarray (TMA) were used for YKT6 expression and prognostic value analyses. The relevance between YKT6 expression, tumor-immune infiltrates and tumor mutation burden (TMB) was examined using the TCGA database. Cellular functional assays were performed to verify the biological behavior of YKT6 in breast cancer cells. Moreover, transcriptome sequencing (RNA-seq) was conducted to explore the underlying mechanism of YKT6. Results: YKT6 was significantly upregulated in breast cancer tissue comparing to normal tissue(P<0.05) and higher YKT6 expression was significantly linked to worse clinical prognosis, advanced tumor stages, and distant metastasis(P<0.05). Additionally, YKT6 expression is correlated with the infiltration of various immune cell and TMB. Knockdown of YKT6 impaired the proliferation, invasion, and migration abilities of breast cancer cells, and increased apoptosis. Functional enrichment analysis revealed that YKT6 primarily influenced breast cancer progression through the cell cycle, as well as biological processes such as autophagy, apoptosis, and ferroptosis. Moreover, knockdown of YKT6 suppressed the activity of mTORC1. Conclusion: YKT6 may serve as a potential prognostic biomarker for breast cancer. The expression level of YKT6 was correlated with tumor-infiltrating immune cells in breast cancer. It may offer potential value for the treatment of breast cancer patients.
- 22 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1742661
Open AccessYKT6 promotes breast cancer progression and is associated with poor prognosis and immune infiltration
Background: YKT6 is markedly overexpressed across multiple tumor types and plays a role in driving their progression. However, the correlation between YKT6 and breast cancer remains poorly understood. Therefore, we aimed to investigate the potential prognostic value and biological function of YKT6 gene in breast cancer. Methods: Public datasets, clinic sample and tissue microarray (TMA) were used for YKT6 expression and prognostic value analyses. The relevance between YKT6 expression, tumor-immune infiltrates and tumor mutation burden (TMB) was examined using the TCGA database. Cellular functional assays were performed to verify the biological behavior of YKT6 in breast cancer cells. Moreover, transcriptome sequencing (RNA-seq) was conducted to explore the underlying mechanism of YKT6. Results: YKT6 was significantly upregulated in breast cancer tissue comparing to normal tissue(P<0.05) and higher YKT6 expression was significantly linked to worse clinical prognosis, advanced tumor stages, and distant metastasis(P<0.05). Additionally, YKT6 expression is correlated with the infiltration of various immune cell and TMB. Knockdown of YKT6 impaired the proliferation, invasion, and migration abilities of breast cancer cells, and increased apoptosis. Functional enrichment analysis revealed that YKT6 primarily influenced breast cancer progression through the cell cycle, as well as biological processes such as autophagy, apoptosis, and ferroptosis. Moreover, knockdown of YKT6 suppressed the activity of mTORC1. Conclusion: YKT6 may serve as a potential prognostic biomarker for breast cancer. The expression level of YKT6 was correlated with tumor-infiltrating immune cells in breast cancer. It may offer potential value for the treatment of breast cancer patients.
- Open Access
- 18 December 2025
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 26 (1) , 2600705
Validation of the important role and prognostic value of KIF14 in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis and limited treatment options. Elevated Kinesin Family Member 14 (KIF14) expression in breast cancer (BC) is correlated with poor prognosis, but its role in TNBC remains unclear. KIF14 expression was analyzed using TCGA, TIMER, and GEO databases, and its association with prognosis was assessed via Kaplan‒Meier plotter. Functional assays, including CCK-8, wound healing, and Transwell assays, were performed to evaluate KIF14's impact on TNBC cell proliferation, migration, and invasion. GO and KEGG analyses of transcriptome data were used to explore molecular mechanisms. The relationship between KIF14 expression and immune infiltration was assessed in the TIMER database. KIF14 expression in clinical samples was validated using qRT-PCR and immunohistochemistry, and its correlation with clinical features was examined. KIF14 was significantly upregulated in BC (P < 0.05), and elevated KIF14 expression was associated with poor prognosis. KIF14 knockdown reduced cell proliferation, migration, and invasion. Network analysis revealed its involvement in lipid metabolism, NF-κB, PI3K-AKT, and mTOR signaling pathways. Immune infiltration analysis showed a significant association between KIF14 and immune cell types. KIF14 promotes TNBC progression and serves as a potential diagnostic and prognostic biomarker for TNBC.
- 18 December 2025
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 26 (1) , 2600705
Open AccessValidation of the important role and prognostic value of KIF14 in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis and limited treatment options. Elevated Kinesin Family Member 14 (KIF14) expression in breast cancer (BC) is correlated with poor prognosis, but its role in TNBC remains unclear. KIF14 expression was analyzed using TCGA, TIMER, and GEO databases, and its association with prognosis was assessed via Kaplan‒Meier plotter. Functional assays, including CCK-8, wound healing, and Transwell assays, were performed to evaluate KIF14's impact on TNBC cell proliferation, migration, and invasion. GO and KEGG analyses of transcriptome data were used to explore molecular mechanisms. The relationship between KIF14 expression and immune infiltration was assessed in the TIMER database. KIF14 expression in clinical samples was validated using qRT-PCR and immunohistochemistry, and its correlation with clinical features was examined. KIF14 was significantly upregulated in BC (P < 0.05), and elevated KIF14 expression was associated with poor prognosis. KIF14 knockdown reduced cell proliferation, migration, and invasion. Network analysis revealed its involvement in lipid metabolism, NF-κB, PI3K-AKT, and mTOR signaling pathways. Immune infiltration analysis showed a significant association between KIF14 and immune cell types. KIF14 promotes TNBC progression and serves as a potential diagnostic and prognostic biomarker for TNBC.
- Open Access
- 22 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Neoadjuvant radiochemotherapy is safe and feasible for breast conserving surgery or immediate reconstruction
This study aimed to evaluate the survival outcomes of neoadjuvant radiochemotherapy (NARCT) for early breast cancer. Female patients ≤ 80 years old with unilateral T1-T4 invasive ductal breast cancer treated with neoadjuvant chemotherapy (NAC) and radiation therapy (RT) between 2006 and 2015 were enrolled from SEER database. Baseline differences in clinical and pathological characteristics were evaluated using chi-square test. The survival outcomes were estimated by Kaplan–Meier analysis and compared using Cox hazards models. The effects of baseline differences on survival outcome in patients treated with neoadjuvant radiation therapy (NART) and post-operation radiation therapy (PORT) were circumvented by propensity score matching (PSM). Altogether 14,151 patients receiving NAC and RT were enrolled, among whom 386 underwent NART. Based on a 1:4 PSM cohort, NART was an independent unfavorable prognostic factor for breast cancer-specific survival (BCSS) and overall survival (OS) for the whole cohort. However, among patients receiving breast conserving surgery (BCS) (HR 1.029, P = 0.915 for BCSS; HR 1.003, P = 0.990 for OS) or implant-based immediate breast reconstruction (IBR) (HR 1.039, P = 0.921 for BCSS; HR 1.153, P = 0.697 for OS), those treated with NART had similar survival outcomes compared with patients treated with PORT. In conclusion, NARCT was a safe and feasible approach for patients undergoing BCS and IBR.
- 22 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessNeoadjuvant radiochemotherapy is safe and feasible for breast conserving surgery or immediate reconstruction
This study aimed to evaluate the survival outcomes of neoadjuvant radiochemotherapy (NARCT) for early breast cancer. Female patients ≤ 80 years old with unilateral T1-T4 invasive ductal breast cancer treated with neoadjuvant chemotherapy (NAC) and radiation therapy (RT) between 2006 and 2015 were enrolled from SEER database. Baseline differences in clinical and pathological characteristics were evaluated using chi-square test. The survival outcomes were estimated by Kaplan–Meier analysis and compared using Cox hazards models. The effects of baseline differences on survival outcome in patients treated with neoadjuvant radiation therapy (NART) and post-operation radiation therapy (PORT) were circumvented by propensity score matching (PSM). Altogether 14,151 patients receiving NAC and RT were enrolled, among whom 386 underwent NART. Based on a 1:4 PSM cohort, NART was an independent unfavorable prognostic factor for breast cancer-specific survival (BCSS) and overall survival (OS) for the whole cohort. However, among patients receiving breast conserving surgery (BCS) (HR 1.029, P = 0.915 for BCSS; HR 1.003, P = 0.990 for OS) or implant-based immediate breast reconstruction (IBR) (HR 1.039, P = 0.921 for BCSS; HR 1.153, P = 0.697 for OS), those treated with NART had similar survival outcomes compared with patients treated with PORT. In conclusion, NARCT was a safe and feasible approach for patients undergoing BCS and IBR.
- Open Access
- 12 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Chemotherapy is of prognostic significance to metaplastic breast cancer
This study aimed to evaluate the significance of chemotherapy (CT) among metaplastic breast cancer (MpBC), and to compare the survival outcomes between triple negative MpBC (MpBC-TNBC) and triple negative invasive ductal carcinoma (IDC-TNBC). SEER database was indexed to identify female unilateral primary MpBC diagnosed from 2010 to 2017. Patients were classified into neoadjuvant chemotherapy (NAC) with response (NAC-response), NAC-no response, adjuvant chemotherapy, and no CT. Breast cancer-specific survival (BCSS) and overall survival (OS) was estimated using the Kaplan–Meier method and compared by log-rank test. Cox regression was used to evaluate the independent prognostic factors. A 1:4 propensity score matching method was adopted to balance baseline differences. Altogether 1186 MpBC patients were enrolled, among them 181 received NAC, 647 received adjuvant CT and 358 did not receive any CT. Chemotherapy was an independent favorable prognostic factor. NAC-response and adjuvant CT had a significant or an obvious trend of survival improvement compared with NAC-no response or no CT. MpBC-TNBC was an independent unfavorable prognostic factor compared with IDC-TNBC. Among them, there was significant or trend of survival improvement among all TNBCs receiving NAC or adjuvant CT compared with no CT. Chemotherapy was of important significance to MpBC prognosis and should be integrated in comprehensive treatment for MpBC.
- 12 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Open AccessChemotherapy is of prognostic significance to metaplastic breast cancer
This study aimed to evaluate the significance of chemotherapy (CT) among metaplastic breast cancer (MpBC), and to compare the survival outcomes between triple negative MpBC (MpBC-TNBC) and triple negative invasive ductal carcinoma (IDC-TNBC). SEER database was indexed to identify female unilateral primary MpBC diagnosed from 2010 to 2017. Patients were classified into neoadjuvant chemotherapy (NAC) with response (NAC-response), NAC-no response, adjuvant chemotherapy, and no CT. Breast cancer-specific survival (BCSS) and overall survival (OS) was estimated using the Kaplan–Meier method and compared by log-rank test. Cox regression was used to evaluate the independent prognostic factors. A 1:4 propensity score matching method was adopted to balance baseline differences. Altogether 1186 MpBC patients were enrolled, among them 181 received NAC, 647 received adjuvant CT and 358 did not receive any CT. Chemotherapy was an independent favorable prognostic factor. NAC-response and adjuvant CT had a significant or an obvious trend of survival improvement compared with NAC-no response or no CT. MpBC-TNBC was an independent unfavorable prognostic factor compared with IDC-TNBC. Among them, there was significant or trend of survival improvement among all TNBCs receiving NAC or adjuvant CT compared with no CT. Chemotherapy was of important significance to MpBC prognosis and should be integrated in comprehensive treatment for MpBC.
- 29 June 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (9) , 3912-3925
The Added Prognostic Value of Oncotype Recurrence Score to AJCC Prognostic Staging System in Stage III ER+/HER2− Breast Cancer
Introduction Prognostic prediction based on prognostic stage (PS) with the Oncotype DX recurrence score (RS) has not been validated in stage III ER+/HER2− breast cancer. This study aimed to evaluate the added prognostic significance of RS incorporated with the PS system and to compare the prognostic prediction improvement with anatomic TNM stage (AS) using nomogram construction. Methods The SEER database was indexed to identify ER+/HER2− invasive ductal or lobular breast cancer in AS IIIA–IIIC with RS results diagnosed from 2004 to 2013. Patients with RS < 18, 18–30 and > 30 were categorized into low-, intermediate- and high-risk RS groups. Comparisons of the distribution of clinical-pathologic characteristics among RS risk groups were performed using Pearson's chi-square test. Breast cancer-specific survival (BCSS) was estimated using the Kaplan-Meier method and compared across RS or PS by log-rank test. Cox regression was used to evaluate the factors independently related to BCSS. A nomogram comprised of PS and RS was constructed with discrimination, calibration and clinical benefit evaluated. Results Altogether 629 patients who received RS were enrolled. There were 326 cases (51.8%) with low-risk RS, 237 (37.7%) with intermediate-risk RS and 66 (10.5%) with high-risk RS; 344 patients (54.7%) had PS IB, 84 (13.4%) had IIB, 150 (23.8%) had IIIA, 46 (7.3%) had IIIB, and only 5 had (0.8%) IIIC. Both PS and RS were independent prognostic factors for BCSS. There were significant or trends of differences in survival among RS within subtypes stratified by PS. There were significant differences in survival among PS only within intermediate-risk RS. A nomogram prediction 5-year BCSS was constructed with a c-index of 0.811. Lower histologic grade, positive PR and fewer positive lymph nodes were independently correlated with low-risk RS. Conclusion PS incorporated with RS had improved prognostic significance for stage III ER+/HER 2− breast cancer.
- 29 June 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (9) , 3912-3925
The Added Prognostic Value of Oncotype Recurrence Score to AJCC Prognostic Staging System in Stage III ER+/HER2− Breast Cancer
Introduction Prognostic prediction based on prognostic stage (PS) with the Oncotype DX recurrence score (RS) has not been validated in stage III ER+/HER2− breast cancer. This study aimed to evaluate the added prognostic significance of RS incorporated with the PS system and to compare the prognostic prediction improvement with anatomic TNM stage (AS) using nomogram construction. Methods The SEER database was indexed to identify ER+/HER2− invasive ductal or lobular breast cancer in AS IIIA–IIIC with RS results diagnosed from 2004 to 2013. Patients with RS < 18, 18–30 and > 30 were categorized into low-, intermediate- and high-risk RS groups. Comparisons of the distribution of clinical-pathologic characteristics among RS risk groups were performed using Pearson's chi-square test. Breast cancer-specific survival (BCSS) was estimated using the Kaplan-Meier method and compared across RS or PS by log-rank test. Cox regression was used to evaluate the factors independently related to BCSS. A nomogram comprised of PS and RS was constructed with discrimination, calibration and clinical benefit evaluated. Results Altogether 629 patients who received RS were enrolled. There were 326 cases (51.8%) with low-risk RS, 237 (37.7%) with intermediate-risk RS and 66 (10.5%) with high-risk RS; 344 patients (54.7%) had PS IB, 84 (13.4%) had IIB, 150 (23.8%) had IIIA, 46 (7.3%) had IIIB, and only 5 had (0.8%) IIIC. Both PS and RS were independent prognostic factors for BCSS. There were significant or trends of differences in survival among RS within subtypes stratified by PS. There were significant differences in survival among PS only within intermediate-risk RS. A nomogram prediction 5-year BCSS was constructed with a c-index of 0.811. Lower histologic grade, positive PR and fewer positive lymph nodes were independently correlated with low-risk RS. Conclusion PS incorporated with RS had improved prognostic significance for stage III ER+/HER 2− breast cancer.
- Open Access
- 25 September 2022
- Published by Wiley in International Journal of Analytical Chemistry
- Vol. 2022, 1-12
CASP9 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Inflammatory Breast Cancer
Background. Inflammatory breast cancer (IBC) is one of the most rare and aggressive subtypes of primary breast cancer (BC). Our study aimed to explore hub genes related to the pathogenesis of IBC, which could be considered as novel molecular biomarkers for IBC diagnosis and prognosis. Material and Methods. Two datasets from gene expression omnibus database (GEO) were selected. Enrichment analysis and protein-protein interaction (PPI) network for the DEGs were performed. We analyzed the prognostic values of hub genes in the Kaplan-Meier Plotter. Connectivity Map (CMap) and Comparative Toxicogenomics Database (CTD) was used to find candidate small molecules capable to reverse the gene status of IBC. Results. 157 DEGs were selected in total. We constructed the PPI network with 154 nodes interconnected by 128 interactions. The KEGG pathway analysis indicated that the DEGs were enriched in apoptosis, pathways in cancer and insulin signaling pathway. PTEN, PSMF1, PSMC6, AURKB, FZR1, CASP9, CASP6, CASP8, BAD, AKR7A2, ZNF24, SSX2IP, SIGLEC1, MS4A4A, and VSIG4 were selected as hub genes based on the high degree of connectivity. Six hub genes (PSMC6, AURKB, CASP9, BAD, ZNF24, and SSX2IP) that were significantly associated with the prognosis of breast cancer. The expression of CASP9 protein was associated with prognosis and immune cells infiltration of breast cancer. CASP9- naringenin (NGE) is expected to be the most promising candidate gene-compound interaction for the treatment of IBC. Conclusion. Taken together, CASP9 can be used as a prognostic biomarker and a novel therapeutic target in IBC.
- 25 September 2022
- Published by Wiley in International Journal of Analytical Chemistry
- Vol. 2022, 1-12
Open AccessCASP9 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Inflammatory Breast Cancer
Background. Inflammatory breast cancer (IBC) is one of the most rare and aggressive subtypes of primary breast cancer (BC). Our study aimed to explore hub genes related to the pathogenesis of IBC, which could be considered as novel molecular biomarkers for IBC diagnosis and prognosis. Material and Methods. Two datasets from gene expression omnibus database (GEO) were selected. Enrichment analysis and protein-protein interaction (PPI) network for the DEGs were performed. We analyzed the prognostic values of hub genes in the Kaplan-Meier Plotter. Connectivity Map (CMap) and Comparative Toxicogenomics Database (CTD) was used to find candidate small molecules capable to reverse the gene status of IBC. Results. 157 DEGs were selected in total. We constructed the PPI network with 154 nodes interconnected by 128 interactions. The KEGG pathway analysis indicated that the DEGs were enriched in apoptosis, pathways in cancer and insulin signaling pathway. PTEN, PSMF1, PSMC6, AURKB, FZR1, CASP9, CASP6, CASP8, BAD, AKR7A2, ZNF24, SSX2IP, SIGLEC1, MS4A4A, and VSIG4 were selected as hub genes based on the high degree of connectivity. Six hub genes (PSMC6, AURKB, CASP9, BAD, ZNF24, and SSX2IP) that were significantly associated with the prognosis of breast cancer. The expression of CASP9 protein was associated with prognosis and immune cells infiltration of breast cancer. CASP9- naringenin (NGE) is expected to be the most promising candidate gene-compound interaction for the treatment of IBC. Conclusion. Taken together, CASP9 can be used as a prognostic biomarker and a novel therapeutic target in IBC.
- Open Access
- 26 June 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (18) , 6205-6210
Nontraumatic convexal subarachnoid hemorrhage: A case report
Nontraumatic convexal subarachnoid hemorrhage (cSAH) is a rare type of atypical subarachnoid hemorrhage. It mainly presents as a focal and transient neurological deficit with similar manifestations as transient ischemic attack. We report a case of a 64-year-old man who visited the hospital with paroxysmal left-sided numbness and weakness is presented in this study. Computed tomography examination indicated a high-density image of the right frontal-parietal sulcus. Digital subtraction angiography showed severe stenosis at the right anterior cerebral artery A2-A3 junction (stenosis rate approximately 70%). The findings of this case indicate that anterior cerebral artery stenosis may lead to the occurrence of cSAH.
- 26 June 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (18) , 6205-6210
Open AccessNontraumatic convexal subarachnoid hemorrhage: A case report
Nontraumatic convexal subarachnoid hemorrhage (cSAH) is a rare type of atypical subarachnoid hemorrhage. It mainly presents as a focal and transient neurological deficit with similar manifestations as transient ischemic attack. We report a case of a 64-year-old man who visited the hospital with paroxysmal left-sided numbness and weakness is presented in this study. Computed tomography examination indicated a high-density image of the right frontal-parietal sulcus. Digital subtraction angiography showed severe stenosis at the right anterior cerebral artery A2-A3 junction (stenosis rate approximately 70%). The findings of this case indicate that anterior cerebral artery stenosis may lead to the occurrence of cSAH.
- Open Access
- 1 August 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 4653-4663
HOTAIR Facilitates Endocrine Resistance in Breast Cancer Through ESR1/miR-130b-3p Axis: Comprehensive Analysis of mRNA-miRNA-lncRNA Network
Background: To summarize the regulatory role of mRNA-miRNA-lncRNA network associated with endocrine therapy resistance (ETR) in breast cancer. Methods: We analyzed the differentially expressed genes (DEGs), differentially expressed lncRNAs (DELs), and differentially expressed miRNAs (DEMs) in long-term estrogen-deprived (LTED) estrogen receptor (ER)-positive breast cancer cells (LTED MCF7) (modeling relapse on endocrine therapy) and MCF7 cells in the presence of estrogen (E2) (modeling a patient at primary diagnosis) by mining GSE120929 and GSE120930 datasets. The mRNA-miRNA-lncRNA network was constructed by multiple bioinformatic tools. The prognosis of genes from the network was validated in breast cancer patients with following systemic treatment (endocrine therapy) by GEPIA, Kaplan–Meier plotter and UALCAN database. Results: Totally, 769 DEGs, 33 DEMs, and 10 DELs were selected. The mRNA-miRNA-lncRNA network was established including 60 mRNA nodes, 6 miRNA nodes and 3 lncRNA nodes. A significant module containing 3 nodes and 3 edges was calculated based on the mRNA-miRNA-lncRNA network. The hub genes in the network are ABCG2, ESR1 and GJA1. ESR1/miR-130b-3p/HOTAIR are significantly correlated with the prognosis of breast cancer patients with endocrine therapy. Conclusion: This study provides a novel ETR-related mRNA-miRNA-lncRNA network. Further, we suggest that ESR1/miR-130b-3p/HOTAIR may be promising targets for clinical treatment of endocrine therapy-resistant breast cancer.
- 1 August 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 4653-4663
Open AccessHOTAIR Facilitates Endocrine Resistance in Breast Cancer Through ESR1/miR-130b-3p Axis: Comprehensive Analysis of mRNA-miRNA-lncRNA Network
Background: To summarize the regulatory role of mRNA-miRNA-lncRNA network associated with endocrine therapy resistance (ETR) in breast cancer. Methods: We analyzed the differentially expressed genes (DEGs), differentially expressed lncRNAs (DELs), and differentially expressed miRNAs (DEMs) in long-term estrogen-deprived (LTED) estrogen receptor (ER)-positive breast cancer cells (LTED MCF7) (modeling relapse on endocrine therapy) and MCF7 cells in the presence of estrogen (E2) (modeling a patient at primary diagnosis) by mining GSE120929 and GSE120930 datasets. The mRNA-miRNA-lncRNA network was constructed by multiple bioinformatic tools. The prognosis of genes from the network was validated in breast cancer patients with following systemic treatment (endocrine therapy) by GEPIA, Kaplan–Meier plotter and UALCAN database. Results: Totally, 769 DEGs, 33 DEMs, and 10 DELs were selected. The mRNA-miRNA-lncRNA network was established including 60 mRNA nodes, 6 miRNA nodes and 3 lncRNA nodes. A significant module containing 3 nodes and 3 edges was calculated based on the mRNA-miRNA-lncRNA network. The hub genes in the network are ABCG2, ESR1 and GJA1. ESR1/miR-130b-3p/HOTAIR are significantly correlated with the prognosis of breast cancer patients with endocrine therapy. Conclusion: This study provides a novel ETR-related mRNA-miRNA-lncRNA network. Further, we suggest that ESR1/miR-130b-3p/HOTAIR may be promising targets for clinical treatment of endocrine therapy-resistant breast cancer.
- 9 July 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (S3) , 826-827
ASO Author Reflections: Breast-Conserving Surgery Could be Performed Safely in Well-Selected T1–T2 Centrally Located Breast Cancer
- 9 July 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (S3) , 826-827
ASO Author Reflections: Breast-Conserving Surgery Could be Performed Safely in Well-Selected T1–T2 Centrally Located Breast Cancer
- 7 July 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (1) , 330-339
Breast-Conserving Surgery is Oncologically Safe for Well-Selected, Centrally Located Breast Cancer
The aim of this study was to evaluate the long-term survival outcomes of breast-conserving surgery (BCS) in centrally located breast cancer (CLBC) compared
- 7 July 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (1) , 330-339
Breast-Conserving Surgery is Oncologically Safe for Well-Selected, Centrally Located Breast Cancer
The aim of this study was to evaluate the long-term survival outcomes of breast-conserving surgery (BCS) in centrally located breast cancer (CLBC) compared